The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study.
Chen S, Liu D, Chen H, Liao A, Li F, Liu C, Li X, Li S, Zhang Y, Wang Y, Xia M, Guo Q, Miao X, Wen Z, Xu M, Yin H, Chen H, Chen M, Xiao Y.
Chen S, et al. Among authors: xu m.
Aliment Pharmacol Ther. 2022 Jun;55(12):1524-1533. doi: 10.1111/apt.16959. Epub 2022 May 3.
Aliment Pharmacol Ther. 2022.
PMID: 35505467
Clinical Trial.